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Background  3 
Two randomised controlled trials (RCTs) conducted simultaneously in the same Irish university 4 
teaching hospital have shown that provision of STOPP/START recommendations to attending 5 
prescribers by a physician or a pharmacist can reduce in-hospital adverse drug reactions (ADRs) in 6 
older adults (≥ 65 years). The aims of this study were to compare the prescriber implementation rates 7 
of STOPP/START recommendations between the physician approach and the pharmacist approach in 8 
these two RCTs, and to provide a narrative summary of the comparable clinical outcomes.  9 
Methods  10 
Data were extracted from the two RCT published papers and their associated computerised databases 11 
to calculate the percentage (%) prescriber implementation rates for the STOPP/START 12 
recommendations. The chi-square test was used to quantify the differences in prescriber implementation 13 
rates, with differences considered statistically significant where p < 0.05.   14 
Results 15 
Prescriber implementation rates of the STOPP and START recommendations made by the physician 16 
were 81.2% and 87.4% respectively, significantly higher than those made by the pharmacist (39.2% 17 
and 29.5% respectively), p < 0.0001. A greater absolute risk reduction in patients with ADRs was shown 18 
with the physician’s intervention compared to the pharmacist’s intervention (9.3% versus 6.8%).  19 
Conclusion 20 
This study shows that the methods of communication and the medium through which the 21 
STOPP/START recommendations are delivered significantly affect their implementation. Non-22 
implementation of some pharmacist-delivered recommendations may be contributing to preventable 23 
ADRs in older adults. Thus, future research should aim to identify the factors influencing prescriber 24 
3 
 
implementation of pharmacist recommendations in order to inform the design of more effective 1 
pharmacist interventions in optimising older patients’ pharmacotherapy. 2 
 3 
Key points 4 
• Prescribers were significantly more likely to implement STOPP/START recommendations from 5 
one physician approach compared to one pharmacist approach in this Irish university teaching 6 
hospital (p < 0.0001). 7 
 8 
• Increased implementation of the physician’s recommendations may have been an important factor 9 
in preventing a larger proportion of in-hospital ADRs in comparison to the pharmacist’s 10 
intervention. However, cost-effectiveness analyses of these interventions would suggest that only 11 
the pharmacist’s intervention was cost-effective. 12 
 13 
• Future research should aim to identify the barriers and facilitators to prescriber implementation of 14 
hospital pharmacist recommendations so as to inform the design of more effective pharmacist 15 
interventions which target pharmacotherapy optimisation in multi-morbid older adults.   16 
 17 
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1. INTRODUCTION  1 
Potentially inappropriate prescribing (PIP) in multi-morbid older adults continues to be a major 2 
healthcare problem worldwide. PIP encompasses the prescription of potentially inappropriate 3 
medications (PIMs), mis-prescribing (e.g. an inappropriate frequency, dose, or duration), or the failure 4 
to prescribe medications that would likely benefit patients, so-called potential prescribing omissions 5 
(PPOs). Previous studies have demonstrated that PIP is one of the primary causes for adverse drug 6 
reactions (ADRs) in older adults [1, 2]. Identifying PIP instances that could increase the risk of ADRs 7 
is important and, where possible, alternatives should be considered that may be equally effective with 8 
a lower risk of harm to older patients [3]. STOPP (Screening Tool of Older Persons’ Prescriptions) and 9 
START (Screening Tool to Alert doctors to Right Treatment) criteria are well recognised as tools for 10 
identifying PIP instances in older people across multiple healthcare settings [4]. 11 
Two recently published randomised controlled trials (RCTs) conducted in the same large university 12 
teaching hospital in southern Ireland demonstrated a clinically significant absolute risk reduction in 13 
incident ADRs in multi-morbid older adults arising from physician-delivered and pharmacist-delivered 14 
pharmacotherapy recommendations to attending prescribers [5, 6]. Both RCTs included the primary 15 
researcher (physician or pharmacist) providing recommendations based on STOPP/START criteria 16 
version 1 [7] to attending physician prescribers caring for hospitalised older adults.  17 
The primary aim of this study was to compare the prescriber implementation rates of STOPP and 18 
START recommendations from these two RCTs conducted simultaneously in the same Irish university 19 
teaching hospital, where the recommendations were delivered by a physician in one trial and by a 20 
pharmacist in the other trial [5, 6]. Secondary aims were to identify components within the interventions 21 
that may have affected prescriber implementation, to compare the prescriber implementation of the 22 
pharmacist’s STOPP/START recommendations with other pharmacist-delivered recommendations, 23 




2. METHODS 1 
2.1 Study setting and intervention details 2 
Both RCTs were conducted in Cork University Hospital, an 810-bed tertiary referral centre in southern 3 
Ireland. Participants were enrolled within 48 hours of their presentation to hospital with acute illness. 4 
The interventions in both RCTs primarily aimed to reduce non-trivial in-hospital ADRs in older adults 5 
(≥ 65 years), and are briefly summarised as follows: 6 
In both RCTs [5, 6], the primary researcher applied the STOPP/START criteria (version 1) [7] at a 7 
single time point to the medication list of intervention patients within 48 hours of hospital admission, 8 
and placed a printed report in the patient’s clinical records with STOPP/START-based 9 
recommendations. The primary researcher verbally notified the attending prescribers of the 10 
recommendations and answered any clarifying questions that they may have had. 11 
In RCT 1, the physician verbally notified the attending prescribers of the STOPP/START-based 12 
recommendations for all patients [5]; in RCT 2, the pharmacist verbally notified the attending 13 
prescribers of the recommendations for approximately one third of patients, but provided mobile phone 14 
contact details on the printed report in case prescribers wanted verbal clarification on the pharmacist’s 15 
advice [6]. In RCT 2, the pharmacist’s STOPP/START-based recommendations were provided in 16 
conjunction with recommendations based on other medication appropriateness issues, i.e. including 17 
drug-drug interactions, need for renal and hepatic dose adjustments, and other PIP instances identified 18 
utilising Beers criteria (version 3) [7] and PRISCUS criteria [8], as well as issues based on medication 19 
reconciliation, which has been defined as the “process of identifying the most accurate list of all 20 
medications a patient is taking - including name, dosage, frequency, and route - and using this list to 21 
provide correct medications for patients anywhere within the health care system” and “involves 22 
comparing the patient’s current list of medications against the physician’s admission, transfer, and/or 23 
discharge orders” [9]. The medication reconciliation issues in RCT 2 were primarily due to medications 24 
omitted and incorrect doses prescribed on admission [10]. In RCT 1, the physician was a specialist 25 
registrar (senior resident) in geriatric medicine with 3 years of specialist clinical experience [5]. In RCT 26 
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2, the pharmacist was fully registered with 4 years of postgraduate experience in providing 1 
pharmaceutical care to older adults.  2 
Both trials used a cluster randomised design. In each RCT, two lists of attending consultant prescribers 3 
were created such that the combined rates of ADRs in these groups were known to be comparable from 4 
previous work undertaken by this group [11]. Having finalised the lists, one group of attending 5 
consultant prescribers was assigned as the intervention arm of the study and the other was assigned as 6 
the control arm. The intervention clusters in both RCT 1 and RCT 2 included individuals admitted under 7 
the care of specialists in cardiology, respiratory medicine, endocrinology, renal medicine, and 8 
orthopaedics. The intervention cluster in RCT 1 also consisted of patients admitted under the care of 9 
specialists in radiation oncology, whilst the intervention cluster in RCT 2 also included patients 10 
admitted under the care of specialists in rheumatology, general and vascular surgery, and general 11 
internal medicine. To avoid potentially biased enrolment of patients into either arm of the study, the 12 
primary researcher in each RCT approached prospective trial participants in the order of their admission 13 
to the hospital’s emergency department to assess their eligibility for the trial. RCT 1 was conducted 14 
from May 2011 to May 2012. RCT 2 was conducted from June 2011 to July 2012. No patient in either 15 
RCT received the intervention from the other RCT. Patients in the intervention and control groups in 16 
both RCTs received standard medical and pharmaceutical care from physicians and pharmacists who 17 
routinely work in the hospital. Implementation of recommendations was assessed by the primary 18 
researcher of each trial at day 7-10 or at the point of hospital discharge (whichever came first). Further 19 
details (e.g. such as study design and patient characteristics) can be found in the published papers 20 
describing these RCTs [5, 6, 10].   21 
2.2 Data Extraction and Analysis 22 
As part of this secondary data analysis, data were extracted from the papers based on the RCTs [5, 6, 23 
10], and their associated computerised databases, stored locally in Microsoft® Access. The percentage 24 
(%) prescriber implementation rates for the STOPP and START recommendations were calculated for 25 
both RCTs. The chi-square test was used to compare the prescriber implementation rates of the STOPP 26 
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and START recommendations in the pharmacist and physician intervention groups, as well as to 1 
quantify any differences between the implementation of STOPP/START recommendations and other 2 
recommendations included in the pharmacist’s intervention. Differences were considered statistically 3 
significant where p < 0.05.   4 
 5 
3. RESULTS  6 
3.1 Prescriber Implementation of STOPP and START recommendations 7 
Tables 1 and 2 show the prescriber implementation rates of STOPP and START recommendations from 8 
the physician and pharmacist respectively, divided according to the relevant physiological systems.  9 
In 360 intervention patients in RCT 1, the physician made 292 STOPP recommendations (0.81/patient) 10 
and 159 START recommendations (0.44/patient) i.e. a total of 1.25 STOPP/START recommendations 11 
per patient.  Attending prescribers implemented 237 of the physician’s 292 STOPP recommendations 12 
(81.2%) and 139 of the physician’s 159 START recommendations (87.4%). In 361 intervention patients 13 
in RCT 2, the pharmacist made 255 STOPP recommendations (0.71/patient), and 44 START 14 
recommendations (0.12/patient) i.e. a total of 0.83 STOPP/START recommendations per patient. 15 
Attending prescribers implemented 100 of the pharmacist’s 255 STOPP recommendations (39.2%) and 16 
13 of the pharmacist’s 44 START recommendations (29.5%).  17 
In total, attending prescribers implemented 83.4% of the physician’s STOPP/START recommendations 18 
(376/451) compared to 37.8% of the pharmacist’s STOPP/START recommendations (113/299). When 19 
comparing the physician and pharmacist interventions, there was a statistically significant difference 20 
between prescriber implementation rates of the total STOPP, total START, and total STOPP/START-21 
combined recommendations (p < 0.0001).  22 
Of the ten categories of STOPP criteria, recommendations were made by both physician and pharmacist 23 
across eight of these categories. The physician achieved higher implementation rates than the 24 
pharmacist for recommendations across all eight STOPP categories, with the absolute differences 25 
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ranging from 11.1% to 55.5%. The largest absolute difference observed was for recommendations based 1 
on the gastrointestinal system. This was primarily due to the low implementation rate of pharmacist 2 
recommendations to deprescribe PPIs (38/115), which was the most common type of STOPP/START 3 
recommendation provided in both RCTs. There were statistically significant differences in the 4 
implementation rates of recommendations across six of the eight STOPP categories, with the exceptions 5 
being recommendations based on urogenital system drugs and analgesic drugs. Of the six categories of 6 
START criteria, recommendations were made by both physician and pharmacist across three of these 7 
categories. The physician achieved statistically significantly higher implementation rates than the 8 
pharmacist for recommendations across all three START categories, with the absolute differences 9 
ranging from 51.7% to 70%.  10 
Of the 65 individual STOPP criteria, recommendations based on 22 of these were prevalent in both 11 
RCTs. The physician achieved higher implementation rates than the pharmacist for recommendations 12 
based on 19 of these 22 STOPP criteria, for which statistically significant differences were observed 13 
for 7 of these 19 STOPP recommendations, as shown in Table 1. The pharmacist achieved a higher 14 
implementation rate than the physician for recommendations based on one of the STOPP criteria – 15 
STOPP rule A8: “Calcium channel blockers with chronic constipation (may exacerbate constipation)” 16 
- but this difference was not statistically significant (9/11 versus 2/4; p = 0.2178). Of the 22 individual 17 
START criteria, recommendations based on 8 of these criteria were prevalent in both RCTs. The 18 
physician achieved higher implementation rates than the pharmacist for recommendations linked to 6 19 
of these 8 START criteria, for which statistically significant differences were observed for 3 of these 6 20 
START recommendations, as shown in Table 2. The pharmacist achieved a higher implementation rate 21 
than the physician for recommendations based on one of the START criteria – START rule A3: “Aspirin 22 
or clopidogrel with a documented history of atherosclerotic coronary, cerebral or peripheral vascular 23 
disease in patients with sinus rhythm”; once again, this difference was not statistically significant (2/5 24 




3.2 Number of recommendations made and focus of intervention 1 
Of the 360 patients randomised to the intervention arm in RCT 1, the physician made 451 2 
recommendations in 233 patients (1.94 recommendations per patient). Of the 361 patients randomised 3 
to the intervention arm in RCT 2, the pharmacist made 1000 recommendations in 296 patients (3.38 4 
recommendations per patient). Thus, for patients where pharmacotherapy recommendations were 5 
provided, the pharmacist provided 1.44 more recommendations per patient in comparison to the 6 
physician.   7 
In RCT 2, the pharmacist’s STOPP/START recommendations represented almost 30% of the total 8 
number of recommendations (299/1000), and 51.8% (299/577) of the medication appropriateness 9 
recommendations (i.e. including drug-drug interactions, need for renal and hepatic dose adjustments, 10 
and other PIP instances identified utilising Beers criteria (version 3) [7] and PRISCUS criteria [8]) [10]. 11 
The remainder of the pharmacist’s recommendations concerned issues with medication reconciliation 12 
(n = 423), of which 326 were implemented (77.1%). The implementation rate of the pharmacist’s 13 
recommendations concerning medication reconciliation recommendations was approximately double 14 
the rate of those concerning STOPP/START criteria (77.1% versus 37.8%;              p < 0.0001). 15 
3.3 Pharmacist Medication Reconciliation recommendations based on START criteria 16 
On initial viewing of the START recommendations in both RCTs, it is evident that the physician made 17 
3.67 times more START recommendations per patient in RCT 1 compared to the pharmacist in RCT 2 18 
(0.44 START/patient versus 0.12 START/patient). The physician did not conduct medication 19 
reconciliation, whereas the pharmacist did. Therefore, as part of the pharmacist’s intervention, there 20 
were 322 recommendations to prescribe “missing medications” (i.e. medications that were prescribed 21 
prior to admission but omitted from the patient’s list of medications on admission), of which 71 (22.0%) 22 
would have been identified by the START criteria based on the patients’ lists of prescribed medications 23 
on admission and comorbidities (as shown in Appendix 1). Fifty-eight of these recommendations were 24 
implemented (81.7%). Prescribers were therefore substantially more likely to implement a 25 
recommendation from a pharmacist to initiate a START criteria-based drug if it had previously been 26 
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prescribed by a physician rather than based on the pharmacist’s recommendation alone (81.7% versus 1 
29.5%; p < 0.0001).  2 
If the 71 recommendations to prescribe START criteria-based “missing medications” were factored in 3 
to the comparison between implementation of physician-delivered and pharmacist-delivered 4 
STOPP/START recommendations (Appendix 2), the physician would still achieve statistically 5 
significantly higher implementation rates for: 6 
(a)  the total START recommendations: 139/159 (87.4%) versus 71/115 (61.7%); p < 0.0001, and 7 
(b) the total STOPP/START recommendations: 376/451 (83.4%) versus 171/370 (46.2%);                   p 8 
< 0.0001. 9 
3.4 Clinical Outcomes 10 
The comparable clinical outcomes from the two RCTs are displayed in Appendix 3. The physician’s 11 
intervention resulted in an absolute reduction of 9.3% in the proportion of patients who experienced a 12 
non-trivial in-hospital ADR in comparison to the control group, compared to the pharmacist’s 13 
intervention which resulted in an absolute reduction of 6.8% for this same outcome. The corresponding 14 
relative risk reductions for this outcome were 44.3% and 32.9% respectively. Neither intervention 15 
resulted in significant differences in median length of hospital stay or mortality when compared to 16 
controls.  17 
 18 
4. DISCUSSION  19 
There is a paucity of research comparing pharmacists and physicians in the provision of 20 
pharmacotherapy recommendations in hospitalised older adults. This is the first study to compare 21 
prescriber implementation rates of STOPP/START recommendations from one approach by a trained 22 
clinical pharmacist with another approach by a physician trained in geriatric medicine. Our results have 23 
shown that the source of the STOPP/START recommendations and the communication methods 24 
11 
 
through which they are provided may have a substantial impact on their implementation. We found that 1 
physician prescribers in this particular hospital in southern Ireland were statistically significantly more 2 
likely to implement STOPP/START recommendations from the physician’s approach and delivery than 3 
from the pharmacist’s in these two RCTs. There was a greater disparity between the two approaches in 4 
the implementation of START recommendations (87.4% versus 29.5%) compared to the 5 
implementation of STOPP recommendations (81.2% versus 39.2%).  6 
A small sample size may have prevented showing statistically significant differences in the prescriber 7 
implementation rates of certain STOPP or START recommendations between physician and 8 
pharmacist. Nevertheless, our study has demonstrated that the physician obtained statistically 9 
significantly higher implementation rates than the pharmacist for 10 of the 30 individual 10 
STOPP/START recommendations present in both interventions, including recommendations to 11 
deprescribe benzodiazepines and proton pump inhibitors. In recent years, there has been extensive 12 
research on deprescribing of these drugs in particular [12-14]. The present study is consistent with 13 
previous findings that geriatricians may be more effective than other healthcare professionals with 14 
deprescribing in hospitalised older adults [14, 15].  15 
The authors recognise that differences between the interventions, other than the individual healthcare 16 
professionals, may have had an influence on prescriber implementation rates, such as: 17 
- The pharmacist provided other recommendations, not just STOPP/START recommendations as the 18 
physician did. 19 
- Both the pharmacist and physician provided all of the recommendations in written form. The 20 
physician also communicated all recommendations verbally, whereas the pharmacist verbally 21 
communicated approximately one third of these recommendations. 22 
- The physician had previously worked in the hospital prior to RCT commencement, whereas the 23 
pharmacist had not. 24 
The physician-delivered intervention was narrowly focused on providing recommendations based on 25 
the STOPP/START criteria only, whereas the pharmacist’s intervention involved the provision of 26 
12 
 
recommendations based on STOPP/START as well as a wider range of drug-related problems. As 1 
previously stated, the pharmacist provided 1.44 more recommendations on average per patient than the 2 
research physician to attending prescribing teams. A recent systematic review suggests that 3 
computerised interventions which target a broader range of PIP issues in older adults may contribute to 4 
information overload, and consequently result in fewer recommendations being implemented [16]. 5 
Thus, in the present study, the greater complexity of the pharmacist intervention compared to the 6 
physician intervention may have resulted in a lower implementation rate of pharmacotherapy 7 
recommendations by attending prescribers.  8 
Previous studies have shown that pharmacists and physicians prefer the use of verbal or face-to-face 9 
recommendations when working in collaboration to review pharmacotherapy [17, 18]. 10 
Recommendations communicated in this way are usually implemented at a higher rate than those 11 
provided by written means alone [19-22]. This suggests that the pharmacist might have achieved higher 12 
implementation rates if he had provided verbal reinforcement to prescribers regarding all the 13 
recommendations in the printed report. However, the high implementation rate of the pharmacist’s 14 
medication reconciliation recommendations (77.1%) suggests that the mode of delivery of the 15 
pharmacist’s recommendations may not have been the primary cause of the observed difference in 16 
STOPP and START recommendation implementation rates between the pharmacist and physician. 17 
Moreover, the contrast in implementation between pharmacist medication reconciliation 18 
recommendations and STOPP/START recommendations is noteworthy. This difference suggests that 19 
there may be an impediment to prescriber implementation of pharmacist interventions relating to 20 
prescribing appropriateness in older patients, and that physicians may be more accepting of the 21 
pharmacist’s role in medication reconciliation as distinct from prescribing alterations.  22 
Both the pharmacist and the physician were highly familiar with the STOPP/START criteria prior to 23 
the start of the two RCTs. Previous studies have demonstrated that inter-rater reliability amongst 24 
pharmacists and physicians is high when provided with the same clinical information [23, 24]. 25 
Therefore, identification of PIP by either healthcare professional should not have been different. A key 26 
factor in achieving implementation of prescribing recommendations may be who provides them, and 27 
13 
 
how they are delivered to prescribers. Physicians may be more likely to implement recommendations 1 
from fellow physicians, as this is customary practice in healthcare systems worldwide. Physicians may 2 
be less likely to implement pharmacist recommendations but the reasons for this are not fully 3 
understood. A qualitative study by Hughes et al [25] found that some pharmacists felt that doctors 4 
considered them to be subordinate on a professional level in relation to medication issues. In that study, 5 
hierarchical differences were implicit in the doctors’ comments as they questioned the role of 6 
pharmacists in certain areas, such as having greater involvement with prescribing decisions, which some 7 
doctors viewed to be solely within the professional domain of the doctor. The same study suggested 8 
that this may be because of some doctors’ lack of awareness of pharmacist training, as well as some 9 
doctors feeling that greater pharmacist involvement would encroach on their prescribing role. Most of 10 
the studies in this area of research are focused on the relationships between pharmacists and physicians 11 
in primary care, and there appears to be limited research into exploring the factors affecting physician 12 
implementation of pharmacist recommendations in secondary care settings [25-27]. 13 
Prior to commencement of the RCTs, the research physician had previously worked in the same hospital 14 
training in geriatric medicine at specialist registrar (senior resident) level. As a result, this particular 15 
physician may have already established a good professional rapport with some of the attending 16 
prescribers prior to RCT 1. This, in turn, may have contributed to an increased implementation of the 17 
STOPP/START recommendations offered by the research physician. In contrast, whilst the research 18 
pharmacist was experienced in providing pharmaceutical care for older adults, he had not previously 19 
worked in the hospital where the RCTs were conducted. Previous research has highlighted that key 20 
components to physician-pharmacist collaboration are trust and ‘knowing’ each other [28], and that 21 
pharmacists who work closely with physicians are more likely to be successful in optimising geriatric 22 
pharmacotherapy [29]. These inter-professional barriers may have contributed to the observed lower 23 
implementation rate of the pharmacist’s STOPP/START recommendations described in this study. 24 
Published studies providing details on prescriber implementation of pharmacist and physician 25 
STOPP/START recommendations are limited. An earlier RCT conducted by a physician in the same 26 
hospital (where medication appropriateness was the primary outcome measure) demonstrated a very 27 
14 
 
high level of prescriber implementation of both the STOPP (91%) and START (97%) recommendations 1 
[30]. Although this intervention took place in the hospital where the STOPP/START criteria were 2 
developed, it is unlikely that this is the reason for the high implementation rates as the criteria are not 3 
routinely applied to older patients there due to resource constraints. The implementation rates of the 4 
pharmacist’s STOPP and START recommendations in this present study seem to be lower than those 5 
described in the literature to date (STOPP: 44% – 94% and START: 58%) [31, 32]. Therefore, our 6 
results support previous findings which indicate that a lower proportion of pharmacist-provided 7 
STOPP/START recommendations are implemented by prescribers in comparison to those provided by 8 
physicians.   9 
There are some limitations to this study. Firstly, although both the original pharmacist and physician 10 
interventions encompass STOPP and START recommendations, they were not designed to be directly 11 
compared. Differences between the interventions cannot be ruled out as possible contributing factors to 12 
the difference in outcomes observed. Secondly, this was a single-centre comparison between the 13 
prescriber implementation rates of recommendations provided by one pharmacist and one physician. 14 
Evaluating implementation of STOPP and START recommendations from a larger sample of 15 
pharmacists and physicians in a multi-centre RCT setting would provide a more accurate comparison 16 
of the professions on this matter, as we recognise that different personalities and communication styles 17 
also vary between individuals, which may impact on the implementation rates. 18 
A cost-effectiveness analysis of the pharmacist intervention has shown that it was cost-effective [33]. 19 
However, a more recent cost-effectiveness analysis indicates that the physician intervention was 20 
unlikely to be cost-effective [34], even though it was associated with a greater absolute risk reduction 21 
in patients with ADRs compared to the pharmacist intervention. The present study suggests that a higher 22 
prescriber implementation rate of STOPP recommendations in particular is associated with lower rates 23 
of incident ADRs in hospitalised older adults. Therefore, it could be argued that the lower 24 
implementation rate of some of the pharmacist’s recommendations resulted in a higher rate of incident 25 
ADRs in the pharmacist RCT intervention cohort. Previous studies have consistently shown that 26 
pharmacists contribute to reductions in healthcare costs in the hospital setting [35]. If physicians are 27 
15 
 
less likely to be cost-effective in conducting interventions of this type, it is important that other ways to 1 
enhance the implementation of pharmacist recommendations are identified, which reliably lead to 2 
further reductions in ADRs, and subsequently lower healthcare costs.  3 
 4 
5. CONCLUSION 5 
This study shows that the methods of communication and the medium through which the 6 
STOPP/START recommendations are provided may have a significant impact on their 7 
implementation. Qualitative research is necessary to identify the key factors affecting prescriber 8 
implementation of hospital pharmacist recommendations, along with possible ideas for future 9 
intervention, as non-implementation of these recommendations probably contribute to preventable 10 
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STOPP criteria Physician Pharmacist p-value 
Cardiovascular System 22/26   (84.6%)  14/26   (53.9%)   0.0162* 
Digoxin at a long-term dose > 125micrograms per day with impaired renal function 1/1 - - 
Loop diuretic for dependent ankle oedema only 4/6 1/2 0.6733 
Loop diuretic as first- line monotherapy for hypertension 4/4 0/1   0.0253* 
Non-cardioselective beta-blocker with COPD or asthma  9/9 2/7   0.0022* 
Beta-blocker in combination with verapamil 1/1 - - 
Calcium channel blockers with chronic constipation 2/4 9/11 0.2178 
Use of aspirin and warfarin in combination without histamine H2 receptor antagonist 
or proton pump inhibitor (high risk of gastrointestinal bleeding) 
- 1/4 - 
Aspirin at dose > 150mg day  - 1/1 - 
Aspirin without coronary, cerebral or peripheral arterial symptoms or occlusive 
arterial event 
1/1 - - 
Central Nervous System 37/46   (80.4%) 15/33   (45.5%)   0.0012* 
Tricyclic antidepressants with dementia 3/3 - - 
Tricyclic antidepressants with glaucoma 1/1 - - 
Tricyclic antidepressants in chronic constipation 3/3 3/4 0.3496 
Tricyclic antidepressants in combination with an opiate or calcium channel blocker 1/1 6/8 0.5708 
Long-term (>1month) use of long-acting benzodiazepines 16/25 4/16   0.0148* 
Long-term (>1 month) use of neuroleptics as hypnotics 4/4 - - 
Long-term (>1 month) use of neuroleptics in those with parkinsonism 2/2 1/1 ‡ 
Phenothiazines in patients with epilepsy  - 0/1 - 
SSRIs with a history of clinically significant hyponatraemia  5/5 1/1 ‡ 
Prolonged use (>1week) of 1st generation antihistamines 2/2 0/2   0.0455* 
Gastrointestinal System 85/96   (88.5%) 39/118   (33%) < 0.0001* 
Prochlorperazine or metoclopramide with parkinsonism - 1/3 - 
PPI for peptic ulcer disease at full therapeutic dose for >8 weeks 85/96 38/115 < 0.0001* 
Respiratory System - 1/3   (33.3%) - 
Theophylline as monotherapy for COPD - 1/1 - 
Nebulised ipratropium with glaucoma - 0/2 - 
Musculoskeletal System 15/20   (75%) 5/13   (38.5%)      0.0358* 
NSAID with history of peptic ulcer disease or gastrointestinal bleeding unless with 
concurrent H2 receptor antagonist, misoprostol or PPI 
2/2 - - 
NSAID with moderate-severe hypertension 4/6 3/5 0.819 
NSAID with heart failure 1/1 0/1 0.1573 
Long-term (> 3 months) use of NSAIDs for symptom relief in mild osteoarthritis 6/9 1/3 0.3105 
Warfarin and NSAID together - 1/4 - 
NSAIDs with chronic renal failure 2/2 - - 
Urogenital System 9/12   (75%) 3/7   (42.9%) 0.1612 
Bladder anti-muscarinic drugs with dementia 4/7 1/2 0.8577 
Anti-muscarinic drugs with glaucoma 1/1 - - 
Anti-muscarinic drugs with chronic constipation 3/3 2/5 0.0897 
Alpha-blockers in males with frequent incontinence (≥ 1 episode daily) 1/1 - - 
Endocrine System - 0/1   (0%) - 
Beta-blockers in those with diabetes mellitus and frequent hypoglycaemic episodes  - 0/1 - 
Drugs that adversely affect those prone to falls 30/46   (65.2%) 12/36   (33.3%)   0.0042* 
Benzodiazepines 19/27 10/26   0.0196* 
Neuroleptic drugs 3/5 1/4 0.2937 
1st generation antihistamines 2/2 0/2   0.0455* 
Vasodilator drugs in those with persistent postural hypotension 1/1 - - 
Long-term opiates 5/11 1/4 0.4745 





Analgesic drugs 16/18   (88.9%) 7/9   (77.8%) 0.4436 
Regular opiates for >2 weeks in those with constipation without concurrent laxatives  12/14 7/9 0.6241 
Use of long-term powerful opiates as first line therapy for mild-moderate pain 2/2 - - 
Long-term opiates in those with dementia unless indicated for palliative care or 
moderate-severe chronic pain syndrome 
2/2 - - 
Duplicate drug class prescriptions 23/28   (82.1%) 4/9   (44.4%)   0.0267* 
Total 237/292 (81.2%) 100/255 (39.2%) < 0.0001* 
COPD: Chronic Obstructive Pulmonary Disease. SSRI: Selective Serotonin Reuptake Inhibitor. PPI: Proton Pump Inhibitor. 























START criteria Physician Pharmacist p-value 
Cardiovascular System 29/37   (78.4%) 4/15   (26.7%)   0.0005* 
Warfarin with chronic atrial fibrillation 15/18 - - 
Aspirin with chronic atrial fibrillation where warfarin is contraindicated 2/3 0/1 0.2482 
Aspirin or clopidogrel with a documented history of atherosclerotic coronary, 
cerebral or peripheral vascular disease in patients with sinus rhythm 
0/2 2/5 0.2899 
Antihypertensive therapy where systolic blood pressure consistently >160 mmHg 1/1 - - 
Statin therapy with history of coronary, cerebral, or peripheral artery disease 
without contraindication 
8/9 1/3 0.0543 
ACE-inhibitor with chronic heart failure 3/4 1/4 0.1573 
ACE-inhibitor following acute myocardial infarction. - 0/1 - 
Beta-blocker with chronic stable angina - 0/1 - 
Gastrointestinal System 1/1   (100%) - - 
Proton Pump Inhibitor with severe gastro-oesophageal acid reflux disease or peptic 
stricture requiring dilatation 
1/1 - - 
Musculoskeletal System 97/109   (89%) 6/19   (31.6%) < 0.0001* 
Bisphosphonates in patients taking maintenance oral corticosteroid therapy 14/18 1/10   0.0006* 
Calcium and vitamin D supplementation in patients with known osteoporosis, 
fragility fracture or dorsal kyphosis 
83/91 5/9   0.0017* 
Endocrine System 12/12   (100%) 3/10   (30%)   0.0004* 
Metformin with type 2 diabetes mellitus +/- metabolic syndrome 1/1 - - 
ACE-inhibitor or angiotensin 2 receptor blocker in patients with diabetes and 
nephropathy 
7/7 - - 
Antiplatelet therapy in those with diabetes mellitus and one or more major 
cardiovascular risk factors 
2/2 1/1 ‡ 
Statin therapy in patients with diabetes mellitus and one or more major 
cardiovascular risk factors 
2/2 2/9   0.0386* 
Total 139/159 (87.4%)  13/44 (29.5%) < 0.0001* 
Table 2: Prescriber Implementation Rates for START Recommendations: Physician versus Pharmacist 
 
ACE: Angiotensin Converting Enzyme.      †p-value calculated using chi-squared test.      * Statistically significant difference observed (p < 0.05).        
‡ p-value cannot be calculated. 
 
